T-DM1 is an experimental targeted therapy medicine that's a combination of Herceptin (chemical name: trastuzumab) and a chemotherapy medicine called maytansine. Researchers are studying T-DM1 to see if it would be a good treatment for HER2-positive, advanced-stage breast cancer that has stopped responding to other treatments.
Cancer medicines are usually considered for FDA approval when the results of a large study (called a phase III clinical trial) are available. Still, some cancer medicines are considered for "accelerated approval" based on the results of one or more smaller studies. Accelerated approval usually is considered when results from one or more smaller, phase II clinical trials suggest that the new medicine may be a good option for people who haven't responded or stopped responding to other available treatments already approved by the FDA.
The U.S. Food and Drug Administration (FDA) decided to not consider accelerated approval for T-DM1 to treat HER2-positive, advanced-stage breast cancer based on phase II clinical trial results available as of August 2010. Still, researchers will continue to study T-DM1 and the medicine may be considered for approval in the future, possibly in 2012 when phase III study results are expected to be available.
WASHINGTON (MedPage Today) -- The Food and Drug Administration turned down a request for accelerated approval of Roche-Genentech's trastuzumab-DM1 drug for the treatment of HER2-positive breast cancer.
The FDA concluded that the supporting data for trastuzumab-DM1 did not meet the Biologic License Application (BLA) Standard for accelerated approval because all available treatment choices for metastatic breast cancer -- irrespective of HER2 status -- had not been exhausted.
Roche had requested accelerated approval on the basis of a single-arm phase II study showing that trastuzumab-DM1 led to tumor responses in a third of patients with advanced HER2-positive breast cancer. Patients in the trial had received an average of seven prior regimens.
An ongoing phase III study will continue as planned. In a statement from the company, Roche officials said they expect a global regulatory submission for trastuzumab-DM1 by the middle of 2012.
Trastuzumab-DM1 is an antibody-drug conjugate, also known as an armed antibody. Conjugate links trastuzumab with the chemotherapy agent DM1, using a stable linker that keeps the agent in one piece until it reaches its target cancer cells, according to a Roche statement. The antibody is designed to bind and penetrate HER2-positive cancer cells and then release the active drug inside the cells to destroy them.
Roche is headquartered in Basel, Switzerland. Genentech, based in San Francisco, Calif., is a unit of Roche.
Breastcancer.org is a non-profit organization dedicated to providing information and community to those touched by this disease. Learn more about our commitment to providing complete, accurate, and private breast cancer information.
Breastcancer.org 7 East Lancaster Avenue, 3rd Floor Ardmore, PA 19003
©2011 Breastcancer.org - All rights reserved.
